Navigation Links
Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Date:11/23/2009

PRINCETON, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The decision was reached after a scheduled review by an independent Data Monitoring Committee (DMC) of all available safety data from the first cohort of approximately 100 patients completing 8 or 12 weeks of RG7128 or matching placebo in combination with pegylated interferon and ribavirin.

The DMC reviewed any potential drug discontinuations, incidence and details of adverse events, and selected laboratory assessments. No safety events in the DMC review were considered significantly different from those expected from HCV patients taking pegylated interferon and ribavirin treatment. The committee expressed no safety concerns that would preclude enrollment of the remaining 300 patients in the ongoing phase 2b study in the HCV positive genotype 1 and 4 population, and have not recommended modification of dose or duration of any RG7128 dosing regimens. Enrollment of these patients pre-screened for this Cohort in the fourth quarter 2009 has begun and is expected to be complete by the end of the first quarter of 2010.

"We welcome Roche's decision to open enrollment of Cohort 2 for the remaining 300 patients in the phase 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "We are encouraged by the safety profile of RG7128 to date, which, when coupled with the higher barrier to resistance offered by nucleoside and nucleotide analog inhibitors has the potential to improve SVR rates over the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), a ... commercialization of novel bile acid therapeutics to treat chronic ... public offering of 1,730,000 shares of its common stock ... In addition, Intercept has granted the underwriters a 30-day ... of common stock. All of the shares ...
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)... , June 18, 2013  Recent regulatory and ... for Medical Education groups at large pharmaceutical companies to ... safe and effective use of their new products. With ... industry, it is crucial that these "Med Ed" ... professionals. To address the changes that are ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... Muscular Dystrophy Association ( MDA ) has awarded $750,000 to ... development of an experimental drug that may become a viable ... The funding comes from MDA Venture Philanthropy (MVP), ... is one of nine types of muscular dystrophy, a group ...
... panel of experts has recommended changes to the guidelines ... suffering from severe chronic pain. The 2011 Polyanalgesic Consensus ... in chronic pain management for the purpose of updating ... improving the technical quality of care in chronic pain. ...
Cached Medicine Technology:MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 3MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 42011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 22011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 32011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 42011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 52011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 6
(Date:6/19/2013)... Sudden cardiac arrest can strike anyone, even a child, ... 5 minutes after cardiac arrest, but the average emergency medical ... death is highly probable if an automated external defibrillator or ... response to this dire reality, US Representative Lois Capps (CA-24) ... 2308) which would provide support for AED and CPR training ...
(Date:6/19/2013)... Middletown, NJ (PRWEB) June 19, 2013 Anant ... is changing and changing rapidly. The first industrial revolution began ... of the textile industry… when the factory was born. The ... Henry Ford mastered the moving assembly line and ushered in ... under way in the 21st century. Manufacturing is going digital ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Indosoft ... Center ACD for Asterisk, announced today the ... 5.7. This enhancement offers improved options for extracting, ... dashboards for effective contact center management. , Large ... real-time captured as it happens from the call ...
(Date:6/19/2013)... June 19, 2013 CoachingWebsites, ... for coaches, announced today its affiliation with ... will offer exclusive websites and marketing solutions and ... “This new partnership with Active Intelligence shows our ... to its fullest,” says Greer Van Dyck, Online ...
(Date:6/19/2013)... The Mesothelioma Victims Center says, "According to ... 3000 citizens, who will be diagnosed with a rare ... third will be US Navy Veterans. We can assure ... form of cancer, or their family members that we ... skilled mesothelioma compensation settlement attorneys, who actually do have ...
Breaking Medicine News(10 mins):Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3
... Some patients with advanced nonsmall-cell lung cancer (NSCLC) have ... drug cisplatin than another platinum-based drug carboplatin, according ... the National Cancer Institute. The authors conclude that cisplatin ... patients. ,Most clinicians in North America prefer ...
... likely to have elevated markers of inflammation, called inflammatory ... distinguished the men with low testosterone was a ... and diabetes risk factors related to this type of ... more likely to have the metabolic syndrome than men ...
... 2002, fifteen months after the 9/11 terrorist attacks, President George ... Eisenhower Executive Office Building next door to the White ... in laboratories, and we believe that regimes hostile to the ... information that a smallpox attack is imminent. Yet it is ...
... According to a study in the June 6 issue of ... of colorectal tumors. Some previous studies have suggested that ... ,Bernard F. Cole, Ph.D., of Dartmouth Medical School, Hanover, ... prevention of new colorectal adenomas in persons with a history ...
... like some phantasy. They live longer than almost anyone in ... vaccinated, and such scourges of the poor as parasites, ... see a doctor, at low cost, right in the neighborhood. ... indeed stupendous. The recent Michael Moore documentary pouring scorn on ...
... make some of us gain more weight than others- ... molecule called BSX, as scientists from the European ... Nutrition [DIFE], Potsdam, and the University of Cincinnati report ... ,Bsx is the molecular link between spontaneous physical activity ...
Cached Medicine News:Health News:Low Levels of Testosterone may Increase the Risk of Death in Older Men 2Health News:Low Levels of Testosterone may Increase the Risk of Death in Older Men 3Health News:New Smallpox Vaccine Contract: Five Years in the Making 2Health News:The Risk of Colorectal Tumor is Not Reduced With Folic Acid Supplements 2Health News:Cuba is Exporting Healthcare Now 2Health News:Cuba is Exporting Healthcare Now 3Health News:Cuba is Exporting Healthcare Now 4Health News:Cuba is Exporting Healthcare Now 5Health News:Molecular Basis of Obesity-Revealing the Unknown Facts 2
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... Kendall provides hospitals and alternate ... of tracheostomy care trays which offer ... infection control. Designed with the guidance ... total-care trays provide exactly what is ...
Medicine Products: